Hepatitis C Therapy: Other Players in the Game

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 641-656

  Ahn, Joseph ^a   Flamm, Steven L ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cyclophilin inhibitor; Hepatitis C; Therapeutic vaccine; Thiazolide; TLR agonist

Indexed keywords

ALISPORIVIR; ALPHA GLUCOSIDASE INHIBITOR; ANA 773; ANA 975; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BAVITUXIMAB; CF 102; CTS 1027; CYCLOPHILIN INHIBITOR; CYT 107; DARINAPARSIN; EMRICASAN; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; HEPAVAXX C; HUMAX HEPC; IDX 320; IDX 375; IMMUNOMODULATING AGENT; IMO 2125; INTERFERON; ISATORIBINE; JKB 122; LGD 4665; MATRIX METALLOPROTEINASE INHIBITOR; MIRAVIRSEN; MONOCLONAL ANTIBODY; MX 3235; NITAZOXANIDE; NOV 025; NOV 205; OGLUFANIDE; PEGINTERFERON; PF 03491390; PI 88; POLYCLONAL ANTIBODY; PYN 17; REP 9C; RIBAVIRIN; SCY 635; SD 101; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; ERADICATION THERAPY; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; REVIEW; VIRUS INHIBITION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CYCLOPHILINS; DRUG DISCOVERY; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; VACCINATION;

EID: 80051943544     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.008     Document Type: Review

References (74)

1. Sklan E.H., Charuworn P., Pang P.S., et al. Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol 2009, 6(4):217-227.
2. Chevaliez S., Pawlotsky J.M. HCV genome and life cycle. Hepatitis C viruses: genomes and molecular biology 2006, 1-43. Horizon Bioscience, Norfolk (UK). S.L. Tan (Ed.).
3. Liu Z., Yang F., Robotham J.M., et al. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 2009, 83:6554-6565.
4. Watashi K., Ishii N., Hijikata M., et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005, 19:111-122.
5. Inoue K., Sekiyama K., Yamada M., et al. Combined interferon alpha 2b and cyclosporine A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003, 38:567-572.
6. Paeshuyse J., Kaul A., De Clercq E., et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006, 43:761-770.
7. Coelmont L., Kaptein S., Paeshuyse J., et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009, 53:967-976.
8. Flisiak R., Horban A., Gallay P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008, 47:817-826.
9. Flisiak R., Feinman S.V., Jablkowski M., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009, 49(5):1460-1468.
10. Flisiak R., Woynarowski M., Jablkowski M., et al. Efficacy of standard of care therapy following experimental DEBIO 025 treatment in patients with chronic hepatitis C. J Hepatol 2010, 52:S291.
11. Nelson D.R., Ghalib R.H., Sulkowski M., et al. Efficacy and safety of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a and ribavirin in previously null-responder genotype 1 HCV patients. J Hepatol 2009, 50:S40.
12. Hopkins S., Scorneaux B., Huang Z., et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 2010, 54:660-672.
13. Hopkins S., Heuman D., Gavis E., et al. Safety, plasma pharmacokinetics and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J Hepatol 2009, 50:S36.
14. Hopkins S., Mosier S., Harris R., et al. Resistance selection following 15 days of monotherapy with SCY-635 a non-immunosuppressive cyclophilin inhibitor with potent anti-HCV activity. J Hepatol 2010, 52:S15.
15. Lawitz E., Rouzier R., Nguyen T., et al. Safety and antiviral efficacy of 14 days of the cyclophilin inhibitor NIM811 in combination with pegylated interferon alpha 2a in relapsed genotype I HCV infected patients. J Hepatol 2009, 50:S379.
16. Wring S., Wille K., Rewerts C., et al. In vitro models for assessing the relative risk of hyperbilirubinemia associated with cyclophilin inhibitor therapy. J Hepatol 2010, 52(S1):S263.
17. Elazar M., Liu M., McKenna S.A., et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2a via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009, 137:1827-1835.
18. Korba B.E., Montero A.B., Farrar K., et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008, 77:56-63.
19. Korba B.E., Elazar M., Lui P., et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 2008, 52:4069-4071.
20. Rossignol J.F., Kabil S.M., El-Gohary Y., et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008, 28:574.
21. Rossignol J.F., Elfert A., El-Gohary Y., et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009, 136:856-862.
22. Rossignol J., Elfert A., Keeffe E.B. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol 2010, 44:504-509.
23. Shiffman M.L., Ahmed A., Jacobson I.M., et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic hepatitis C genotype 1: final report. J Hepatol 2010, 52:S461.
24. Bacon B.R., Shiffman M.L., Lim J.K., et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naïve patients: week 12 sustained virologic response rate. J Hepatol 2010, 52:S463.
25. Korba B., Elazar M., Liu P., et al. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology 2008, 48:356A.
26. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011, 239:99-108.
27. Yu C.I., Chiang B.L. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010, 1-12.
28. Haller A.A., Lauer G.M., King T.H., et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007, 25(8):1452-1463.
29. Habersetzer F., Baumert T.F., Soll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009, 11:456-462.
30. Schiff E., Everson G., Tsai N., et al. HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: a randomized, double blind, placebo controlled phase 1B study. Hepatology 2007, 46:816A.
31. Jacobson I.M., McHutchison J.G., Boyer T.D., et al. GI-5005 therapeutic vaccine plus peg-IFN/ribavirin significantly improves virologic response and ALT normalization at end-of-treatment and improves SVR24 compared to peg-IFN/ribavirin in genotype-1 chronic HCV patients. J Hepatol 2010, 52:S465-S466.
32. McHutchison J.G., Goodman Z.D., Everson G.T., et al. GI-5005 therapeutic vaccine plus peg-IFN/ribavirin improves biopsy necro-inflammatory scores and ALT normalization at 48 weeks versus peg-IFN/ribavirin in genotype 1 chronic HCV patients. J Hepatol 2010, 52:S116.
33. Pockros P., Jacobson I.M., Boyer T.D., et al. GI-5005 Therapeutic vaccine plus Peg-IFN/Ribavirin improves sustained virologic response versus Peg-IFN/Ribavirin in prior non-responders with genotype 1 chronic HCV infection. Hepatology 2010, 50(4):LB-6.
34. McHutchison J.G., Thompson A.J., Jacobson I.M., et al. Pharmacogenomic analysis reveals improved virologic response in all IL-28b genotypes in naive genotype 1 chronic HCV patients treated with GI-5005 therapeutic vaccine plus peg-IFN/ribavirin. J Hepatol 2010, 52:S457.
35. Vierling J.M., McHutchison J.G., Jacobson I.M., et al. GI-5005 therapeutic vaccine improves deficit in cellular immunity in IL28B genotype T/T, treatment-naive patients with chronic hepatitis C genotype 1 when added to standard of care (SOC) Peg-IFN-alfa-2A/Ribavirin. Hepatology 2010, 52(4):A1973.
36. Sallberg M., Frelin L., Diepolder H., et al. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. J Hepatol 2009, 50(S1):S18-S19.
37. Leroux-Roels G., Batens A.H., Desombere I., et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005, 1(2):61-65.
38. Firbas C., Jilma B., Tauber E., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006, 24:4343-4353.
39. Klade C.S., Wedemeyer H., Berg T., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with peptide vaccine IC41. Gastroenterology 2008, 134:1385-1395.
40. Wedemeyer H., Schuller E., Schlaphoff V., et al. Therapeutic vaccine IC41 as late add-onto standard treatment in patients with chronic hepatitis C. Vaccine 2009, 27:5142-5151.
41. Habersetzer F., Zarski J.P., Leroy V., et al. A novel vectorized HCV therapeutic vaccine (Tg4040): results of a phase I study in naive patients chronically infected by HCV. J Hepatol 2009, 50:S18.
42. Yutani S., Yamada A., Yoshida K., et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to response to interferon-based therapy. Vaccine 2007, 25(42):7429-7435.
43. Yutani S., Komatsu N., Shichijo S., et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci 2009, 100(10):1935-1942.
44. Drane D., Maraskovsky E., Gibson R., et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009, 5(3):151-157.
45. Alvarez-Lajonchere L., Shoukry N.H., Gra B., et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat 2009, 16(3):156-167.
46. Frey S.E., Houghton M., Coates S., et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010, 28:6367-6373.
47. Leav B.A., Sloan S., Blair B.M., et al. Safety and pharmacokinetics of a novel human monoclonal antibody directed against the E2 glycoprotein of hepatitis C virus (MBL-HCV1) in healthy volunteers. J Hepatol 2010, 52:S118.
48. Willems J., Ede M., Marotta P., et al. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J Hepatol 2002, 36:S32.
49. Davis G.L., Nelson D.R., Terrault N., et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005, 11:941-949.
50. Godofsky E., Shan J. Phase I single dose study of bavituximab, a chimeric antiphosphatidylserine monoclonal antibody, in subjects with chronic hepatitis C. Hepatology 2006, 44:236A.
51. Galun E., Terrault N.A., Eren R., et al. Clinical evaluation (phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 2007, 46:37-44.
52. Schiano T.D., Charlton M., Younossi Z., et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006, 12:1381-1389.
53. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
54. Muir A., Ghalib R., Lawitz E., et al. A phase 1, multi-center, randomized, placebo-controlled, dose-escalation study of IMO-2125, a TLR9 agonist, in hepatitis C nonresponders. J Hepatol 2010, 52:S14.
55. Horsmans Y., Berg T., Desager J.P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724-731.
56. Xiang A.X., Webber S.E., Kerr B.M., et al. Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids 2007, 26:635-640.
57. Cianciara J., Martin J.T., Spellman M.C. Phase 1B dose-escalation study of SD-101, a novel therapeutic TLR-9 agonist, in treatment-naïve chronic hepatitis C patients. J Hepatol 2010, 52:S126.
58. Ciancio A., Rizzetto M. Thymalfasin in the treatment of hepatitis B and C. Ann N Y Acad Sci 2010, 1194:141-146.
59. Gane E.J., Orr D.W., Weilert F., et al. Phase II study of the mitochondrial antioxidant mitoquinone for hepatitis C. J Hepatol 2008, 48:S318.
60. Ahmed-Belkacem A., Ahnou N., Barbotte L., et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010, 138:1112-1122.
61. Polyak S.J., Morishima C., Shuhart M.C., et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007, 132:1925.
62. Biermer M., Stoehr L., Schlosser B., et al. Silibinin as a rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Hepatol 2010, 52:S16.
63. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs 2009, 10:860-870.
64. Zeuzem S., Yoshida E.M., Benhamou Y., et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008, 48:407-417.
65. Zeuzem S., Sulkowski M.S., Lawitz E.J., et al. Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010, 139:1257-1266.
66. Nelson D.R., Benhamou Y., Chuang W.L., et al. Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010, 139:1267-1276.
67. Brand S., Zitzmann K., Dambacher J., et al. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL28A and IL-29. Biochem Biophys Res Commun 2005, 331:543-548.
68. Freeman J.A., Gray T.E., Fontana D.J., et al. The effect of treatment group, HCV genotype, and IL28B genotype on early HCV viral kinetics in a phase 2a study of PEG-interferon lambda (pegIFNλ) in hepatitis C patients. Hepatology 2010, 50(4):A831.
69. Muir A.J., Lawitz E., Ghalib R.H., et al. Pegylated interferon lambda (pegIFNλ) Phase 2 dose-ranging, active-controlled study in combination with ribavirin (RBV) for treatment-naïve HCV patients (genotypes 1,2,3, or 4): safety, viral response, and impact of IL28B host genotype through week 12. Hepatology 2010, 50(4):A821.
70. Dzyublyk I., Yegorova T., Moroz L., et al. Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon alfa-2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1). Hepatology 2007, 46:863A.
71. Long W.A., Takov D., Tchernev K., et al. Q2week controlled-release-interferon alpha2b+ribavirin reduces flu-like symptoms >50% and provides equivalent efficacy in comparison to weekly pegylated-interferon-alpha2b+ribavirin in treatment-naïve genotype-1-chronic-hepatitis C: results from EMPOWER, a randomized-open-label-12-week-comparison in 133 patients. J Hepatol 2010, 52:S467.
72. Benhamou Y., Afdhal N.H., Nelson D.R., et al. A phase III study of the safety and efficacy of viramidine vs ribavirin in treatment-naïve patients with chronic hepatitis C: VISER 1 results. Hepatology 2009, 50:717-726.
73. Marcellin P., Gish R.G., Gitlin N., et al. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naïve hepatitis C patients. J Hepatol 2010, 52:32-38.
74. Poordad F., Lawitz E., Shiffman M.L., et al. Virologic rates of weight-based taribavirin versus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2010, 52(4):1208-1215.